Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment

Neuroscientist

Volumn 11, Issue 5, 2005, Pages 452-470

  Yang, Charles R ^a   Chen, Long ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Allosteric modulation; D1 receptor; Dopamine; Glutamate; Glycine; Glycine transporter 1; Schizophrenia; Stepholidine

Indexed keywords

DOPAMINE 1 RECEPTOR; GLYCINE; GLYCINE TRANSPORTER 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; COGNITION; HUMAN; MEMORY; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; MODELS, NEUROLOGICAL; NEURAL NETWORKS (COMPUTER); NEURONAL PLASTICITY; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 25144449608     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858405279692     Document Type: Review

References (244)

1. Aakalu G, Smith WB, Nguyen N, Jiang C, Schuman EM. 2001. Dynamic visualization of local protein synthesis in hippocampal neurons. Neuron 30:489-502.
2. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, and others. 2002. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-19.
3. Abi-Dargham A, Moore H. 2003. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9:404-16.
4. Abi-Dargham A, Narendran R, Frankle G, Khenissi L, Gil R, Cooper T, and others. 2003. PET imaging of prefrontal dopamine d1 receptors in chronic PCP/ketamine human abusers: a model for schizophrenia [abstract]. Program No. 234.5. Society for Neuroscience Online.
5. Adams B, Moghaddam B. 1998. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-54.
6. Adams BW, Moghaddam B. 2001. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50:750-7.
7. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, and others. 1999. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-9.
8. Aragon C, Lopez-Corcuera B. 2003. Structure, function and regulation of glycine neurotransporters. Eur J Pharmacol 479:249-62.
9. Ariano MA, Sortwell CE, Ray M, Altemus KL, Sibley DR, Levine MS. 1997. Agonist-induced morphologic decrease in cellular D1A dopamine receptor staining. Synapse 27:313-21.
10. Arnsten AF. 1997. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151-62.
11. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. 1997. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-34.
12. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, and others. 2001. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60:1414-20.
13. Aubrey KR, Vandenberg RJ. 2001. N[3-(4′-fluorophenyl)-3-(4′- phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol 134:1429-36.
14. Aura J, Riekkinen P Jr. 1999. Blockade of NMDA receptors located at the dorsomedial prefrontal cortex impairs spatial working memory in rats. Neuroreport 10:243-8.
15. Benveniste M, Clements J, Vyklicky L Jr, Mayer ML. 1990. A kinetic analysis of the modulation of N-methyl-D-aspartic acid receptors by glycine in mouse cultured hippocampal neurones. J Physiol 428:333-57.
16. Bergeron R, Meyer TM, Coyle JT, Greene RW. 1998. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 95:15730-4.
17. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, and others. 1999. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669-71.
18. Billups D, Attwell D. 2003. Active release of glycine or D-serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse. Eur J Neurosci 18:2975-80.
19. Blank T, Nijholt I, Teichert U, Kugler H, Behrsing H, Fienberg A, and others. 1997. The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses. Proc Natl Acad Sci U S A 94:14859-04.
20. Bliss TV, Collingridge GL. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-9.
21. Bohanick JD, Young CE, Jones CK, Koester A, Hoffman BJ, Yang CR. 2004. NMDA receptor-mediated synaptic and firing responses in glycine transporter (GlyT1a) knockout mice: in vitro and in vivo characterizations. Program No. 167.16. Abstr Soc Neurosci.
22. Borowsky B, Hoffman BJ. 1998. Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure. J Biol Chem 273:29077-85.
23. Borowsky B, Mezey E, Hoffman BJ. 1993. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 10:851-63.
24. Bouvier M. 2001. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2:274-86.
25. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, and others. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-74.
26. Carr DB, Sesack SR. 2000a. GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 38:114-23.
27. Carr DB, Sesack SR. 2000b. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 20:3864-73.
28. Cartmell J, Monn JA, Schoepp DD. 2000. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 148:423-9.
29. Castner SA, Goldman-Rakic PS. 2004. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 24:1446-50.
30. Castner SA, Williams GV, Goldman-Rakic PS. 2000. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287:2020-2.
31. Cépeda C, Buchwald NA, Levine MS. 1993. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A 90:9576-80.
32. Cépeda C, Colwell CS, Itri JN, Chandler SH, Levine MS. 1998. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol 79:82-94.
33. Cépeda C, Colwell CS, Itri JN, Gruen E, Levine MS. 1998. Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons. Eur J Neurosci 10:3491-7.
34. Chen G, Greengard P, Yan Z. 2004. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci U S A 101:2596-600.
35. Chen L, Muhlhauser M, Yang CR. 2003. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89:691-703.
36. Chen L, Yang CR. 2002a. Dopamine D1 receptor modulation of NMDA EPSC exhibits an inverted-U dose-response profile in rat prefrontal cortex (PFC) in vitro. Program No. 336.7. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience.
37. Chen L, Yang CR. 2002b. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-36.
38. Christopoulos A, May LT, Avlani VA, Sexton PM. 2004. G-protein-coupled receptor allosterism: the promise and the problem(s). Biochem Soc Trans 32:873-7.
39. Chuhma N, Zhang H, Masson J, Zhuang X, Sulzer D, Hen R, and others. 2004. Dopamine neurons mediate a fast excitatory signal via their glutamatergic synapses. J Neurosci 24:972-81.
40. Contestabile A. 2000. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev 32:476-509.
41. Craig CG, Temple SD, White TD. 1994. Is cyclic AMP involved in excitatory amino acid-evoked adenosine release from rat cortical slices? Eur J Pharmacol 269:79-85.
42. Cull-Candy S, Brickley S, Farrant M. 2001. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327-35.
43. Cull-Candy SG, Leszkiewicz DN. 2004. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 255:rel6.
44. Curras MC, Pallotta BS. 1996. Single-channel evidence for glycine and NMDA requirement in NMDA receptor activation. Brain Res 740:27-40.
45. Daly DA, Moghaddam B. 1993. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152:61-4.
46. Danysz W, Parsons AC. 1998. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664.
47. Davidson M, Harvey PD, Bergman RL, Powchik P, Kaminsky R, Losonczy MF, and others. 1990. Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry 47:190-1.
48. Davis KL, Kahn RS, Ko G, Davidson M. 1991. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-86.
49. Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, and others. 1995. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 121:317-22.
50. Deutch AY. 1992. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36:61-89.
51. Deutch AY, Duman RS. 1996. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70:377-89.
52. Dingledine R, Kleckner NW, McBain CJ. 1990. The glycine coagonist site of the NMDA receptor. Adv Exp Med Biol 268:17-26.
53. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. 1995. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378:180-2.
54. Dong ZJ, Chen LJ, Jin GZ, Creese I. 1997. GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum. Biochem Pharmacol 54:227-32.
55. Dubnau J, Chiang AS, Tully T. 2003. Neural substrates of memory: from synapse to system. J Neurobiol 54:238-53.
56. Dumartin B, Caille I, Gonon F, Bloch B. 1998. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 18:1650-61.
57. Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. 2004. Dopamine D1-dependent trafficking of striatal n-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 65:121-9.
58. Dunah AW, Standaert DG. 2001. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21:5546-58.
59. Dunwiddie TV, Masino SA. 2001. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31-55.
60. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA. 2003. Impairment in perceptual attentional set-shifting following PCP, administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179:77-84.
61. Emamian ES, Karayiorgou M, Gogos JA. 2004. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J Neurosci 24:1561-41.
62. Fiorentini C, Gardoni F, Spano P, Di Luca M, Missale C. 2003. Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem 278:20196-202.
63. Fleischmann A, Hvalby O, Jensen V, Strekalova T, Zacher C, Layer LE, and others. 2003. Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J Neurosci 23:9116-22.
64. Floresco SB, Phillips AG. 2001. Delay-dependent modulation of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav Neurosci 115:934-9.
65. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, and others. 2002. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol 88:3010-20.
66. French PJ, O'Connor V, Jones MW, Davis S, Errington ML, Voss K, and others. 2001. Subfield-specific immediate early gene expression associated with hippocampal long-term potentiation in vivo. Eur J Neurosci 13:968-76.
67. Frey U, Huang YY, Kandel ER. 1993. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260:1661-41.
68. Gabernet L, Pauly-Evers M, Schwerdel C, Lentz M, Bluethmann H, Vogt K, and others. 2005. Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. Neurosci Lett 373:79-84.
69. Gao WJ, Krimer LS, Goldman-Rakic PS. 2001. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc Natl Acad Sci U S A 98:295-300.
70. Gazi L, Lopez-Gimenez JF, Strange PG. 2002. Formation of oligomers by G protein-coupled receptors. Curr Opin Drug Discov Devel 5:756-03.
71. Geerlings A, Nunez E, Rodenstein L, Lopez-Corcuera B, Aragon C. 2002. Glycine transporter isoforms show differential subcellular localization in PC12 cells. J Neurochem 82:58-65.
72. Gemperle AY, Enz A, Pozza MF, Luthi A, Olpe HR. 2003. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 117:681-95.
73. Glanzer JG, Eberwine JH. 2003. Mechanisms of translational control in dendrites. Neurobiol Aging 24:1105-11.
74. Goldman-Rakic PS. 1996. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A 93:13473-80.
75. Goldman-Rakic PS. 1999. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46:650-61.
76. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. 2004. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174:3-16.
77. Gomeza J, Hulsmann S, Ohno K, Eulenburg V, Szoke K, Richter D, and others. 2003. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 40:785-96.
78. Gomeza J, Ohno K, Betz H. 2003. Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr Opin Drug Discov Devel 6:675-82.
79. Grace AA. 1993. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect 91:111-34.
80. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. 2000. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20:1208-15.
81. Greengard P. 2001. The neurobiology of slow synaptic transmission. Science 294:1024-30.
82. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, and others. 1996. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16:2034-43.
83. Guo N, Hwang DR, Lo ES, Huang YY, Laruelle M, Abi-Dargham A. 2003. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 28:1703-11.
84. Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, and others. 2003. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811-25.
85. Harvey J, Lacey MG. 1997. A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 17:5271-80.
86. Hashimoto A, Oka T. 1997. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 52:325-53.
87. Hashimoto A, Oka T, Nishikawa T. 1995. Extracellular concentration of endogenous free D-serine in the rat brain as revealed by in vivo microdialysis. Neurosci 66:635-43.
88. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ. 2001. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 41:88-96.
89. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. 2004. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55:165-71.
90. Hoffman BJ, Jones CK, Yu H, Gordon K, Ford A, Thompson LK, and others. 2004. Neurochemical characterization of glyt1a null mice: a differential role for glyt1a in amino acid homeostasis in forebrain, brainstem, and cerebellum. Program No. 167.15. Viewer/Itinerary Planner. Abstr Soc Neurosci.
91. Hondo H, Nakahara T, Nakamura K, Hirano M, Uchimura H, Tashiro N. 1995. The effect of phencyclidine on the basal and high potassium evoked extracellular GABA levels in the striatum of freely-moving rats: an in vivo microdialysis study. Brain Res 671:54-62.
92. Huang EP. 1999. Synaptic plasticity: regulated translation in dendrites. Curr Biol 9:R168-70.
93. Huang YY, Kandel ER. 1995. D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci U S A 92:2446-50.
94. Ikemoto S, Kohl RR, McBride WJ. 1997. GABA(A) receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats. J Neurochem 69:137-43.
95. Jackson ME, Frost AS, Moghaddam B. 2001. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens. J Neurochem 78:920-3.
96. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. 2004. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29:300-7.
97. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-8.
98. Jensen AA, Spalding TA. 2004. Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci 21:407-20.
99. Jentsch JD, Dazzi L, Chhatwal JP, Verrico CD, Roth RH. 1998. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci Lett 258:175-8.
100. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-25.
101. Jentsch JD, Taylor JR, Roth RH. 1998. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19:105-13.
102. Jentsch JD, Tran A, Taylor JR, Roth RH. 1998. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berl) 138:89-95.
103. Jiang C, Schuman EM. 2002. Regulation and function of local protein synthesis in neuronal dendrites. Trends Biochem Sci 27:506-13.
104. Jin GZ, Zhu ZT, Fu Y. 2002. (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol Sci 23:4-7.
105. Johnson JW, Ascher P. 1992. Equilibrium and kinetic study of glycine action on the N-methyl-D-aspartate receptor in cultured mouse brain neurons. J Physiol 455:339-65.
106. Johnson KW, Clemens-Smith A, Nomikos G, Davis R, Phebus L, Shannon H, and others. 2003. In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors. Ann N Y Acad Sci 1003:412-4.
107. Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE. 2004. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem Soc Trans 32:881-7.
108. Ju W, Morishita W, Tsui J, Gaietta G, Deerinck TJ, Adams SR, and others. 2004. Activity-dependent regulation of dendritic synthesis and trafficking of AMPA receptors. Nat Neurosci 7:244-53.
109. Kapur S, Mamo D. 2003. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-90.
110. Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C, and others. 1995. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121:328-9.
111. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, and others. 2002. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43:19-29.
112. Keener RP, Dakis M. 1997. Intrahippocampal injections of phencyclidine but not naloxone disrupt acquisition of a spatial continuous recognition memory task. Pharmacol Biochem Behav 56:97-101.
113. Kew JN, Richards JG, Mutel V, Kemp JA. 1998. Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci 18:1935-43.
114. King D, Finlay JM. 1995. Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellular dopamine in neostriatum. Brain Res 685:117-28.
115. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, and others. 2003. The glycine transporter type 1 inhibitor N-[3-(4¢- fluorophenyl)-3-(4¢-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23:7586-91.
116. Klann E, Antion MD, Banko JL, Hou L. 2004. Synaptic plasticity and translation initiation. Learn Mem 11:365-72.
117. Kobayashi T, Ikeda K, Kumanishi T. 2000. Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K+ (GIRK) channels expressed in xenopus oocytes. Br J Pharmacol 129:1716-22.
118. Konradi C. 1998. The molecular basis of dopamine and glutamate interactions in the striatum. Adv Pharmacol 42:729-33.
119. Konradi C, Leveque JC, Hyman SE. 1996. Amphetamine, and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci 16:4231-9.
120. Kötter R. 1994. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 44:163-96.
121. Krystal JH, Anand A, Moghaddam B. 2002. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 59:663-4.
122. Lamelle M, Abi-Dargham A. 1999. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13:358-71.
123. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. 1999. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72.
124. Lavin A, Nogueira L, Lapish CC, Wightman M, Phillips PEM, Seamans JK. 2005. Mesocortical dopamine neurons operate in distinct temporal domains using multimodal signaling. J Neurosci 25:5013-23.
125. Laviolette SR, van der Kooy D. 2001. GABA(A) receptors in the ventral tegmental area control bidirectional reward signalling between dopaminergic and non-dopaminergic neural motivational systems. Eur J Neurosci 13:1009-15.
126. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, and others. 2002. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111:219-30.
127. Lester RA, Tong G, Jahr CE. 1993. Interactions between the glycine and glutamate binding sites of the NMDA receptor. J Neurosci 13:1088-96.
128. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, and others. 2000. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20:4011-20.
129. Levine MS, Altemus KL, Cepeda C, Cromwell HC, Crawford C, Ariano MA, and others. 1996. Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. J Neurosci 16:5870-82.
130. Lewis DA. 1997. Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology 16:385-98.
131. Lewis DA, Volk DW, Hashimoto T. 2004. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174:143-50.
132. Li HB, Matsumoto K, Yamamoto M, Watanabe H. 1997. NMDA but not AMPA receptor antagonists impair the delay-interposed radial maze performance of rats. Pharmacol Biochem Behav 58:249-53.
133. Li Q, Clark S, Lewis DV, Wilson WA. 2002. NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J Neurosci 22:3070-80.
134. Lim R, Hoang P, Berger AJ. 2004. Blockade of glycine transporter-1 (GLYT-1) potentiates NMDA receptor-mediated synaptic transmission in hypoglossal motorneurons. J Neurophysiol 92:2530-7.
135. Lin CW, Bianchi BR, Miller TR, Stashko MA, Wang SS, Curzon P, and others. 1996. Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. J Pharmacol Exp Ther 276:1022-9.
136. Liu J, Guo X, Wang BC, Jin GZ. 1999. Increased phosphorylation of DARPP-32 by D1 agonistic action of 1-stepholidine in the 6-OHDA-lesioned rat striatum. Sheng Li Xue Bao 51:65-72.
137. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. 2000. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 403:274-80.
138. Long JM, Kesner RP. 1995. Phencyclidine impairs temporal order memory for spatial locations in rats. Pharmacol Biochem Behav 52:645-8.
139. Lynch DR, Guttmann RP. 2001. NMDA receptor pharmacology: perspectives from molecular biology. Curr Drug Targets 2:215-31.
140. Lynch DR, Guttmann RP. 2002. Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther 300:717-23.
141. Malenka RC, Nicoll RA. 1999. Long-term potentiation-a decade of progress? Science 285:1870-4.
142. Manzoni OJ, Manabe T, Nicoll RA. 1994. Release of adenosine by activation of NMDA receptors in the hippocampus. Science 265:2098-101.
143. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, and others. 2004. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 557:489-500.
144. May LT, Avlani VA, Sexton PM, Christopoulos A. 2004. Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 10:2003-13.
145. McBain CJ, Mayer ML. 1994. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 74:723-60.
146. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, and others. 2002. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267-71.
147. Millan MJ. 2002. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord 1:191-213.
148. Miller EK, Cohen JD. 2001. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24:167-202.
149. Mizoguchi K, Yuzurihara M, Ishige A, Sasaki H, Chui DH, Tabira T. 2000. Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J Neurosci 20:1568-74.
150. Mockett BG, Brooks WM, Tate WP, Abraham WC. 2004. Dopamine D1/D5 receptor activation fails to initiate an activity-independent late-phase LTP in rat hippocampus. Brain Res 1021:92-100.
151. Moghaddam B. 2003. Bringing order to the glutamate chaos in schizophrenia. Neuron 40:881-4.
152. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-7.
153. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-40.
154. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, and others. 1992. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217-21.
155. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH. 1993. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157:53-6.
156. Ninan I, Wang RY. 2003. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. Eur J Neurosci 17:1306-12.
157. Nisenbaum LK, Figiber HC. 2000. Effects of olanzapine and other antipsychotic drugs on c-fos expression. In: Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G, editors. Olanzapine (Zyprexa): a novel antipsychotic. Baltimore: Williams & Wilkins. p 160-80.
158. Nishi A, Bibb JA, Matsuyama S, Hamada M, Higashi H, Nairn AC, and others. 2002. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J Neurochem 81:832-41.
159. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P. 2000. Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci U S A 97:12840-5.
160. Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P. 2005. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 102:1199-204.
161. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. 1994. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 115:147-56.
162. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, and others. 2003. Glycine binding primes NMDA receptor internalization. Nature 422:302-7.
163. Nong Y, Huang YQ, Salter MW. 2004. NMDA receptors are movin' in. Curr Opin Neurobiol 14:353-61.
164. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, and others. 1997. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-6.
165. Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
166. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW. 1999. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251-70.
167. Parsons CG, Zong X, Lux HD. 1993. Whole cell and single channel analysis of the kinetics of glycine-sensitive N-methyl-D-aspartate receptor desensitization. Br J Pharmacol 109:213-21.
168. Paspalas CD, Goldman-Rakic PS. 2005. Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. J Neurosci 25:1260-7.
169. Patel J, Zinkand WC, Thompson C, Keith R, Salama A. 1990. Role of glycine in the N-methyl-D-aspartate-mediated neuronal cytotoxicity. J Neurochem 54:849-54.
170. Pehek EA, Yamamoto BK. 1994. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63:2118-24.
171. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F. 2004. Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci 24:1149-58.
172. Pistis M, Porcu G, Melis M, Diana M, Gessa G. 2001. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neuroscience 14:96-102.
173. Platenik J, Kuramoto N, Yoneda Y. 2000. Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sci 67:335-64.
174. Ragozzino ME, Kim J, Hassert D, Minniti N, Kiang C. 2003. The contribution of the rat prelimbic-infralimbic areas to different forms of task switching. Behav Neurosci 117:1054-65.
175. Ragozzino ME, Ragozzino KE, Mizumori SJ, Kesner RP. 2002. Role of the dorsomedial striatum in behavioral flexibility for response and visual cue discrimination learning. Behav Neurosci 116:105-15.
176. Rajadhyaksha A, Barczak A, Macias W, Leveque JC, Lewis SE, Konradi C. 1999. L-type Ca(2+) channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons. J Neurosci 19:6348-59.
177. Rees S, Morrow D, Kenakin T. 2002. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 8:261-8.
178. Riehemann S, Volz HP, Stutzer P, Smesny S, Gaser C, Sauer H. 2001. Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test-a fMRI study. Eur Arch Psychiatry Clin Neurosci 251:66-71.
179. Robertson GS, Fibiger HC. 1992. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-28.
180. Romanides AJ, Duffy P, Kalivas PW. 1999. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience 92:97-106.
181. Salter MW. 2003. D1 and NMDA receptors hook up: expanding on an emerging theme. Trends Neurosci 26:235-7.
182. Sawaguchi T, Goldman-Rakic PS. 1991. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251:947-50.
183. Scholz KP, Miller RJ. 1996. Presynaptic inhibition at excitatory hippocampal synapses: development and role of presynaptic Ca2+ channels. J Neurophysiol 76:39-46.
184. Schulman H. 1995. Protein phosphorylation in neuronal plasticity and gene expression. Curr Opin Neurobiol 5:375-81.
185. Schulz S, Siemer H, Krug M, Hollt V. 1999. Direct evidence for biphasic cAMP responsive element-binding protein phosphorylation during long-term potentiation in the rat dentate gyrus in vivo. J Neurosci 19:5683-92.
186. Scott L, Kruse MS, Forssberg H, Brismar H, Greengard P, Aperia A. 2002. Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc Natl Acad Sci U S A 99:1661-4.
187. Seamans JK, Durstewitz D, Christie BR, Stevens CF, Sejnowski TJ. 2001. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 98:301-6.
188. Seamans JK, Floresco SB, Phillips AG. 1998. D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. J Neurosci 18:1613-21.
189. Seamans JK, Nogueira L, Lavin A. 2003. Synaptic basis of persistent activity in prefrontal cortex in vivo and in organotypic cultures. Cereb Cortex 13:1242-50.
190. Seamans JK, Yang CR. 2004. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1-58.
191. Sesack SR, Carr DB. 2002. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav 77:513-7.
192. Shoham S, Javitt DC, Heresco-Levy U. 2001. Chronic high-dose glycine nutrition: effects on rat brain cell morphology. Biol Psychiatry 49:876-85.
193. Smith WB, Starck SR, Roberts RW, Schuman EM. 2005. Dopaminergic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45:765-79.
194. Snyder GL, Fienberg AA, Huganir RL, Greengard P. 1998. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 18:10297-303.
195. Soudijn W, Van Wijngaarden I, Ijzerman AP. 2004. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today 9:752-8.
196. Stefani MR, Groth K, Moghaddam B. 2003. Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav Neurosci 117:728-37.
197. Steffensen SC, Svingos AL, Pickel VM, Henriksen SJ. 1998. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci 18:8003-15.
198. Steward O. 2002. mRNA at synapses, synaptic plasticity, and memory consolidation. Neuron 36:338-40.
199. Steward O, Worley PF. 2001. Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 30:227-40.
200. Steward O, Worley P. 2002. Local synthesis of proteins at synaptic sites on dendrites: role in synaptic plasticity and memory consolidation? Neurobiol Learn Mem 78:508-27.
201. Supplisson S, Roux MJ. 2002. Why glycine transporters have different stoichiometries. FEBS Lett 529:93-101.
202. Sur C, Kinney GG. 2004. The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs 13:515-21.
203. Svenningsson P, Fienberg AA, Allen PB, Moine CL, Lindskog M, Fisone G, and others. 2000. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. J Neurochem 75:248-57.
204. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. 2004. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269-96.
205. Svensson TH, Tung CS. 1989. Local cooling of pre-frontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 136:135-6.
206. Swanson CJ, Schoepp DD. 2002. The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY3 79268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J Pharmacol Exp Ther 303:919-27.
207. Taber MT, Das S, Fibiger HC. 1995. Cortical regulation of subcortical dopamine release: mediation via the ventral tegmental area. J Neurochem 65:1407-10.
208. Taber MT, Fibiger HC. 1995. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors. J Neurosci 15:3896-904.
209. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL. 1986. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 43:398-402.
210. Thompson TL, Moss RL. 1995. In vivo stimulated dopamine release in the nucleus accumbens: modulation by the prefrontal cortex. Brain Res 686:93-8.
211. Thomson AM. 1990. Glycine is a coagonist at the NMDA receptor/channel complex. Prog Neurobiol 35:53-74.
212. Tsai G, Lane HY, Yang P, Chong MY, Lange N. 2004. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452-6.
213. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, and others. 2004. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A 101:8485-90.
214. Van Bockstaele EJ, Pickel VM. 1995. GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. Brain Res 682:215-21.
215. Venator DK, Lewis DA, Finlay JM. 1999. Effects of partial dopamine loss in the medial prefrontal cortex on local baseline and stress-evoked extracellular dopamine concentrations. Neuroscience 93:497-505.
216. Verma A, Moghaddam B. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-9.
217. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. 2000. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43.
218. Volz HP, Gaser C, Hager F, Rzanny R, Mentzel HJ, Kreitschmann-Andermahr I, and others. 1997. Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test-a functional MRI study on healthy volunteers and schizophrenics. Psychiatry Res 75:145-57.
219. Vyklicky L Jr, Benveniste M, Mayer ML. 1990. Modulation of N-methyl-D-aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurones. J Physiol 428:313-31.
220. Wang H, Tiedge H. 2004. Translational control at the synapse. Neuroscientist 10:456-66.
221. Wang Z, Feng XQ, Zheng P. 2002. Activation of presynaptic D1 dopamine receptors by dopamine increases the frequency of spontaneous excitatory postsynaptic currents through protein kinase A and protein kinase C in pyramidal cells of rat prelimbic cortex. Neuroscience 112:499-508.
222. Weinberger DR, Berman KF, Suddath R, Torrey EF. 1992. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149:890-7.
223. Weinberger DR, Gallhofer B. 1997. Cognitive function in schizophrenia. Int Clin Psychopharmacol 12:529-36.
224. Westerink BH, Kwint HF, deVries JB. 1996. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605-11.
225. Westphal RS, Tavalin SJ, Lin JW, Alto NM, Fraser ID, Langeberg LK, and others. 1999. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science 285:93-6.
226. Wheal HV, Chen Y, Mitchell J, Schachner M, Maerz W, Wieland H, and others. 1998. Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity. Prog Neurobiol 55:611-40.
227. Williams GV, Goldman-Rakic PS. 1995. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572-5.
228. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ. 2005. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 313:594-603.
229. Wolf ME. 2002. Addiction: making the connection between behavioral changes and neuronal plasticity in specific pathways. Mol Interv 2:146-57.
230. Worley PF, Bhat RV, Baraban JM, Erickson CA, McNaughton BL, Barnes CA. 1993. Thresholds for synaptic activation of transcription factors in hippocampus: correlation with long-term enhancement. J Neurosci 13:4776-86.
231. Xi ZX, Stein EA. 1998. Nucleus accumbens dopamine release modulation by mesolimbic GABAA receptors-an in vivo electrochemical study. Brain Res 798:156-65.
232. Yamada S, Takaki T, Yokoo H, Tanaka M. 1995. Differential effects of dopamine antagonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. J Pharm Pharmacol 47:259-62.
233. Yamakura T, Shimoji K. 1999. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59:279-98.
234. Yamamoto BK, Cooperman MA. 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14:4159-66.
235. Yamamoto BK, Pehek EA, Meltzer HY. 1994. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55:8-14.
236. Yang CR, Seamans JK, Gorelova N. 1999. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21:161-94.
237. Yang SN. 2000. Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: an essential role of postsynaptic Ca2+. Hippocampus 10:57-63.
238. Yim CY, Mogenson GJ. 1980. Effect of picrotoxin and nipecotic acid on inhibitory response of dopaminergic neurons in the ventral tegmental area to stimulation of the nucleus accumbens. Brain Res 199:466-73.
239. Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H. 1998. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine- induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 341:45-56.
240. You ZB, Tzschentke TM, Brodin E, Wise RA. 1998. Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: an in vivo microdialysis study in freely moving rats. J Neurosci 18:6492-500.
241. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, and others. 1999. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20:403-12.
242. Zafra F, Gomeza J, Olivares L, Aragon C, Gimenez C. 1995. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 7:1342-52.
243. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. 1997. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17:8528-35.
244. Zou LL, Liu J, Jin GZ. 1997. Involvement of receptor reserve in D1 agonistic action of (-)-stepholidine in lesioned rats. Biochem Pharmacol 54:233-40.